Sanofi

News

Sanofi forges new $8bn pact with Regeneron

Sanofi's long-running R&D alliance with Regeneron has gone up a gear with a new deal – including a $1bn upfront payment – that spans four new drugs.

News

AZ's gMG drug Klygefa nears EU approval

AstraZeneca's generalised myasthenia gravis (gMG) therapy Klygefa gets CHMP recommendation, alongside several other novel medicines.

News

A COVID jab held in hands wearing surgical gloves

FDA approves new COVID shots - with same restrictions as las...

FDA has approved the 2026 COVID vaccine formulations, but last year's narrower recommendation stands, leaving open questions about access.

News

Sanofi to lay off 229 Blueprint employees, close offices

A year after its $9.1bn acquisition of Blueprint Medicines, Sanofi is moving out of Blueprint's Cambridge, MA offices and letting 229 employees go.

News

Sanofi drops two more programmes in R&D clear-out

Shortly after terminating one late-stage R&D programme, Sanofi confirmed in its second-quarter update that two others are being scrapped.

News

Sanofi gives up on amlitelimab in atopic dermatitis

Sanofi has stopped development of anti-OX40L drug amlitelimab in atopic dermatitis, a major blow to what was once viewed as a 'pipeline-in-a-product'.

Sanofi forges new $8bn pact with Regeneron

AZ's gMG drug Klygefa nears EU approval

FDA approves new COVID shots - with same restrictions as las...

Sanofi to lay off 229 Blueprint employees, close offices

Sanofi drops two more programmes in R&D clear-out

Sanofi gives up on amlitelimab in atopic dermatitis

argenx's Forte acquisition delivers coeliac trial win

Discover a new era of healthcare panel engagement: Grounded ...

Sanofi

Editor's Picks